浏览全部资源
扫码关注微信
1.广西中医药大学,南宁 530022
2.广西壮族自治区食品药品检验所,南宁 530022
张良,在读硕士,从事心血管药理学研究,E-mail:395949836@qq.com
*马远征,博士,助教,从事肿瘤药理研究,E-mail:Judy11279@163.com
* 李善良,博士,助教,从事心血管药理学研究,E-mail:nice2019gucm@foxmail.com;
纸质出版日期:2021-08-05,
网络出版日期:2021-06-01,
收稿日期:2021-03-19,
扫 描 看 全 文
张良,杨双蓉,李淑莹等.基于网络药理学和实验验证探讨槲皮素治疗心力衰竭的分子机制[J].中国实验方剂学杂志,2021,27(15):156-165.
ZHANG Liang,YANG Shuang-rong,LI Shu-ying,et al.Study on Mechanism of Quercetin in Heart Failure Based on Network Pharmacology and Experimental Validation[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(15):156-165.
张良,杨双蓉,李淑莹等.基于网络药理学和实验验证探讨槲皮素治疗心力衰竭的分子机制[J].中国实验方剂学杂志,2021,27(15):156-165. DOI: 10.13422/j.cnki.syfjx.20210919.
ZHANG Liang,YANG Shuang-rong,LI Shu-ying,et al.Study on Mechanism of Quercetin in Heart Failure Based on Network Pharmacology and Experimental Validation[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(15):156-165. DOI: 10.13422/j.cnki.syfjx.20210919.
目的
2
通过网络药理学和分子对接方法预测槲皮素治疗心力衰竭的治疗靶点及相关信号通路,通过离体细胞模型进一步明确其作用机制。
方法
2
通过SwissTargetPrediction,TargetNet数据库获取槲皮素药理作用相关靶点;通过在线人类孟德尔遗传数据库(OMIM),GeneCards,疗效药物靶点数据库(TTD)数据库获取心力衰竭相关靶点;使用STRING数据库进行蛋白质-蛋白质相互作用(PPI)网络分析,建立槲皮素-心力衰竭靶点PPI网络图;利用Cytoscape 3.7.2软件对槲皮素抗心力衰竭网络节点进行筛选分析,使用DAVID工具平台对所得靶点进行基因本体(GO)与京都基因与基因组百科全书(KEGG)富集分析。利用离体细胞心力衰竭模型,验证药物的抗心力衰竭作用,为药物的基因预测和验证提供基础。
结果
2
预测结果显示槲皮素与心力衰竭相关靶点23个,其中关键靶点11个,包括基质金属蛋白酶-9(MMP-9),雄激素受体(AR),凝血因子2(F2),胰岛素样生长因子1受体(IGF1R),表皮生长因子受体(EGFR),Janus激酶2(JAK2),细胞色素P450家族19A1(CYP19A1),雌激素受体-1(ESR1),肿瘤坏死因子(TNF),C型蛋白酪氨酸激酶受体(PTPRC),细胞色素P450家族17A1(CYP17A1)等。结果提示槲皮素可能具有干预心肌细胞和内皮细胞增殖、能量代谢调控等生理过程的功能,参与调节缺氧诱导因子1(HIF-1)信号通路、类固醇激素生物合成等信号通路。
结论
2
槲皮素治疗心力衰竭具有多靶点-多途径-多通路的特点,作用机制可能与其调节MMP-9,EGFR等关键基因,参与心血管细胞增殖和能量代谢等生物过程相关。
Objective
2
To predict the therapeutic targets and related signaling pathways of quercetin in the treatment of heart failure (HF) by network pharmacology and molecular docking methods,and further clarify its mechanisms through
in vitro
cell model.
Method
2
The pharmacological targets of quercetin were obtained by SwissTargetPrediction and Targetnet databases; the heart failure related targets were obtained by Online Mendelian Inheritance in Man(OMIM),GeneCards and Therapeutic Target Database(TTD) databases; the protein-protein interaction(PPI) network was analyzed by STRING database(Search Tool for Recurring Instances of Neighbouring Genes),and the PPI network diagram of quercetin for heart failure target was established. Cytoscape 3.7.2 software was used for analyzing and screening the anti-heart failure network nodes of quercetin,and the obtained targets were enriched with gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis by DAVID database. In order to explore the mechanism of quercetin in the treatment of heart failure,we used cell model to verify the function in heart failure treatment.
Results
2
The predicted results showed that there were 23 targets for the treatment of heart failure,such as Matrix Metallopeptidase-9(MMP-9),androgen receptor(AR),coagulation factor 2(F2),insulin like growth factor 1 receptor(IGF1R),epidermal growth factor receptor(EGFR),janus kinase-2(JAK2),cytochrome P450 family 19 subfamily A member 1(CYP19A1),estrogen receptor-1(ESR1),tumor necrosis factor(TNF),protein tyrosine phosphatase receptor type C(PTPRC) and cytochrome P450 family 17 subfamily A member 1(CYP17A1) etc. The results suggest that quercetin may play a role in the treatment of heart failure by intervening in the physiological processes of cardiovascular cell proliferation and metabolism,regulating hypoxia-inducible factor 1 (HIF-1)signaling pathway and steroid hormone biosynthesis.
Conclusion
2
Quercetin has the characteristics of multi-target,multi-channel and multi-channel in the treatment of heart failure. It may play a role in the treatment of heart failure by regulating MMP-9,EGFR and other key genes,participating in the biological process of cardiac and vascular cell proliferation and metabolism.
槲皮素网络药理学心力衰竭靶点预测细胞验证
quercetinnetwork pharmacologyheart failuretarget predictioncell validation
佚名.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志,2018,2(4):196-225.
SUJITH D,STEVEN P.Recent Developments in Heart Failure[J].Circ Res,2015,117(7):e58-e63.
AGNES W B,GUIDO R M M H,AALT B.Health effects of quercetin:from antioxidant to nutraceutical[J].Eur J Pharmacol,2008,585(2/3):325-337.
PATAL R V,MISTRY B M,SHINDE S K,et al.Therapeutic potential of quercetin as a cardiovascular agent[J].Eur J Med Chem,2018,155:889-904.
张福宸,刘婧,贾伟佳,等.槲皮素改善慢性心力衰竭模型大鼠心功能的作用机制[J].中国老年学杂志,2021,41(5):1089-1092.
RADOSINSKA J,BARANCIK M,VRBJAR N.Heart failure and role of circulating MMP-2 and MMP-9[J].Panminerva Med,2017,59(3):241-253.
KIVELA R,HEMANTHAKUMAR K A,VAPARANTA K,et al.Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2-mediated paracrine signaling[J].Circulation,2019,139(22):2570-2584.
KUN-YI H,SAMIK G,HIROAKI K.Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology[J].PLoS One,2013,8(12):e83922.
SZKLARCZYK D,GABLE A L,LYON D,et al.STRING v11: protein-protein association networks with increased coverage,supporting functional discovery in genome-wide experimental datasets[J].Nucleic Acids Res,2019,47(D1):607-613.
YOSHIZAWA A,SUMIYOSHI S,SONOBE M,et al.Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients[J].J Thorac Oncol,2013,8(1):52-61.
GRISANTI L A,GUO S,TILLEY D G.Cardiac GPCR-mediated EGFR transactivation: impact and therapeutic implications[J].J Cardiovasc Pharmacol,2017,70(1):3-9.
MULLER E J,SCHWINGER R H.TNF and congestive heart failure: therapeutic possibilities[J].Expert Opin Ther Targets,2004,8(3):203-209.
PUZIANOWSKA K M.ESR1 in myocardial infarction[J].Clinica Chimica Acta,2012,413(1/2):81-87.
申兴桂,徐雪松.蛋白质酪氨酸磷酸酶与药物靶标[J].生命的化学,2007(3):241-243.
何桂媛,李文新,万晓蓉,等.细胞色素P450在急性肺损伤中作用的研究进展[J].山东医药,2018,58(40):91-94.
易东,谈世进.雄激素在心血管疾病中作用的相关信号通路[J].医学研究杂志,2014,43(2):9-11.
MARTINELLI C E,CUSTODIO R J,AGUIAR O M H.Fisiologia do eixo GH-sistema IGF [physiology of the GH-IGF axis] [J].Arq Bras Endocrinol Metabol,2008,52(5):717-725.
MCNAMARA C A,SAREMBOCK I J,BACHHUBER B G,et al.Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis[J].Semin Thromb Hemost,1996,22(2):139-144.
LAKSHMANAN I,PONNUSAMY M P,DAS S,et al.MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells[J].Oncogene,2012,31(7):805-817.
DENNIS G,SHERMAN T B,HOSACK A D,et al.DAVID:database for annotation,visualization,and integrated discovery[J].Genome Biol,2003,4(5):418-427.
BAROUCH L A,HARRISON R W,SKAF M W,et al.Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms[J].Nature,2002,416(6878):337-339.
KUN Y H,SAMIK G,HIROAKI K.Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology[J].PLoS One,2013,8(12):e83922.
王彦霞,廖爱华,柳贵梅,等.丹参注射液对肺心病心衰患者血流变学和血小板聚集功能影响[J].中国中医基础医学杂志,2013,19(5):521-522.
程礼琪,周佩晓,陈婉玲.参附注射液对心力衰竭患者心肌功能的保护作用[J].中医临床研究,2019,11(8):32-33.
TOH H T.Improved isolated heart contractility and mitochondrial oxidation after chronic treatment with Panax ginseng in rats[J].Am J Chin Med,1994,22:275-284.
CHEN X.Cardiovascular protection by ginsenosides and their nitric oxide releasing action[J].Clin Exp Pharmacol Physiol,1996,23(8):728-732.
RAHUL V P,BHUPENDRA M M,SURENDRA K S,et al.Therapeutic potential of quercetin as a cardiovascular agent[J].Eur J Med Chem,2018,155:889-904.
LARSON A J,SYMONS J D,JALILI T.Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms[J].Adv Nutr,2012,3(1):39-46.
SARAH E,ANJA B W,JASMIN SEIBERL.Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype:a double-blinded,placebo-controlled cross-over study[J].Br J Nutr Camb,2009,102(7):1065-1074.
BONDONNO N P,BONDONNO C P,HODGSON J M,et al.The efficacy of quercetin in cardiovascular health[J].Curr Nutr Rep,2015,4(4):290-303.
程杰坤,李乐.心肌肥厚动物模型建立方法研究进展[J].中国药房,2015,26(25):3584-3587.
BEATRIZ M F,RICARDO G.Mitochondria and oxidative stress in heart aging[J].Age (Omaha),2016,38(4):225-238.
BIERHANSL L,CONRADI L C,TREPS L,et al.Central role of metabolism in endothelial cell function and vascular disease[J].Physiology (Bethesda),2017,32(2):126-140.
RUIZ L M,SALAZAR C,JENSEN E,et al.Quercetin affects erythropoiesis and heart mitochondrial function in mice[J].Oxid Med Cell Longev,2015,2015: 836301.
KELLY B D,HACKETT S F,HIROTA K. et al.Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1[J].Circ Res,2003,93(11):1074-1081.
HUANG C K,LEE S O,CHANG E,et al.Androgen receptor (AR) in cardiovascular diseases[J].J Endocrinol,2016,229(1):R1-R16.
SAGER H B,HULSMANS M,LAVINE K J,et al.Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure[J]. Circ Res,2016,119(7):853-864.
MARTINI E,KUNDERFRANCO P,PEANO C,et al. Single-cell sequencing of mouse heart immune infiltrate in pressure overload-driven heart failure reveals extent of immune activation[J].Circulation,2019,140(25):2089-2107.
0
浏览量
23
下载量
4
CSCD
关联资源
相关文章
相关作者
相关机构